このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

AbCellera Biologics 将来の成長

Future 基準チェック /26

AbCellera Biologicsの収益は年間13.5%で減少すると予測されていますが、年間収益は年間22.6%で増加すると予想されています。EPS は年間8.8%で減少すると予想されています。

主要情報

-13.5%

収益成長率

-8.8%

EPS成長率

Life Sciences 収益成長	16.7%
収益成長率	22.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	21 May 2024

今後の成長に関する最新情報

Recent updates

Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

May 29

AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

Nov 29

AbCellera Biologics: Many Reasons To Own This Undervalued Stock

Sep 06

AbCellera Biologics: COVID Antibody Set To Provide Continued Funding

Aug 14

AbCellera partnering with Atlas Ventures on development of therapeutic antibodies

Aug 03

AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying

Jun 06

Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

May 13

Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

May 07

AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment

Apr 22

AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm

Feb 11

AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues

Dec 05

AbCellera Biologics: The COVID Premium Is Gone, Thanks To Merck - Time To Buy

Oct 18

AbCellera Biologics: I Was Wrong

Aug 20

AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Are More Bearish Than They Used To Be

Aug 17

AbCellera Biologics: A Buy At Current Prices

Aug 06

業績と収益の成長予測

NasdaqGS:ABCL - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	66	-218	N/A	N/A	4
12/31/2025	52	-215	N/A	N/A	8
12/31/2024	42	-175	N/A	N/A	11
3/31/2024	36	-147	-128	-42	N/A
12/31/2023	38	-146	-121	-44	N/A
9/30/2023	50	-129	-69	7	N/A
6/30/2023	145	-74	-189	-120	N/A
3/31/2023	181	-50	60	133	N/A
12/31/2022	485	159	205	277	N/A
9/30/2022	603	248	160	230	N/A
6/30/2022	507	200	287	351	N/A
3/31/2022	489	205	166	235	N/A
12/31/2021	375	153	186	245	N/A
9/30/2021	444	177	212	263	N/A
6/30/2021	448	197	219	265	N/A
3/31/2021	431	203	120	133	N/A
12/31/2020	233	85	8	23	N/A
9/30/2020	28	0	8	22	N/A
6/30/2020	23	2	15	25	N/A
3/31/2020	14	-3	-7	0	N/A
12/31/2019	12	-2	-1	3	N/A
12/31/2018	9	0	-2	4	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ABCL今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ABCL今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ABCL今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ABCLの収益 ( 22.6% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: ABCLの収益 ( 22.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ABCLの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

AbCellera Biologics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates decrease by 16%, EPS upgraded

Consensus revenue estimates fall by 20%

Consensus revenue estimates decrease by 16%, EPS upgraded

Price target decreased by 8.0% to US$24.38

Consensus EPS estimates upgraded to US$0.46 loss, revenue downgraded

Consensus EPS estimates increase by 21%

Recent updates

CEO, President & Chairperson exercised options to buy US$212k worth of stock.

Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

AbCellera: Cash Providing Shelter From Market Weakness

Consensus revenue estimates decrease by 16%, EPS upgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

AbCellera Biologics Inc., Annual General Meeting, Jun 13, 2024

AbCellera Biologics Inc. to Report Q1, 2024 Results on May 07, 2024

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

Consensus revenue estimates fall by 20%

AbCellera: Victim Of Its Own Success

AbCellera Biologics Inc. Announces Board Changes

AbCellera Biologics: Continuing To Expand Partnerships

AbCellera Biologics Inc. to Report Fiscal Year 2023 Results on Feb 20, 2024

Abcellera Biologics, Inc. Announces Reorganization

Consensus revenue estimates decrease by 16%, EPS upgraded

AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

AbCellera Biologics Inc. to Report Q3, 2023 Results on Nov 02, 2023

Price target decreased by 8.0% to US$24.38

Consensus EPS estimates upgraded to US$0.46 loss, revenue downgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights' Request for Rehearing

AbCellera Biologics Inc. to Report Q2, 2023 Results on Aug 03, 2023

DAMONA Pharmaceuticals Appoints John Reilly as Member of the Board of Directors

CEO, President & Chairperson exercised options to buy US$391k worth of stock.

Chief Financial Officer recently bought US$99k worth of stock

First quarter 2023 earnings: EPS misses analyst expectations

CEO, President & Chairperson exercised options to buy US$470k worth of stock.

Full year 2022 earnings: EPS and revenues miss analyst expectations

Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

AbCellera Biologics Inc. to Report Fiscal Year 2022 Results on Feb 21, 2023

CEO, President & Chairperson recently bought US$859k worth of stock

Investor sentiment deteriorated over the past week

AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

CEO, President & Chairperson exercised options to buy US$786k worth of stock.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improved over the past week

AbCellera Biologics Inc. to Report Q3, 2022 Results on Nov 08, 2022

Investor sentiment improved over the past week

AbCellera Biologics: Many Reasons To Own This Undervalued Stock

CEO, President & Chairperson recently bought US$2.3m worth of stock

Investor sentiment deteriorated over the past week

AbCellera Biologics: COVID Antibody Set To Provide Continued Funding

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

AbCellera partnering with Atlas Ventures on development of therapeutic antibodies

AbCellera Biologics Inc. to Report Q2, 2022 Results on Aug 09, 2022

AbCellera Biologics Inc. Announces Departure of Neil Berkley as Chief Business Officer

CEO, President & Chairperson recently bought US$515k worth of stock

CEO, President & Chairperson recently bought US$484k worth of stock

AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying

CEO, President & Chairperson exercised options to buy US$443k worth of stock.

CEO, President & Chairperson recently bought US$9.0m worth of stock

Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

Consensus EPS estimates increase by 21%

Price target decreased to US$33.38

AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment

AbCellera Biologics Inc. to Report Q1, 2022 Results on May 10, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Independent Non-Employee Director recently bought US$181k worth of stock

Consensus revenue estimates increase by 66%

CEO, President & Chairperson exercised options to buy US$501k worth of stock.

Investor sentiment deteriorated over the past week

AbCellera Biologics Inc. Announces Bebtelovimab Receive Emergency Use Authorization from the U.S. Food and Drug Administration

AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm

Investor sentiment improved over the past week